Suchergebnisse - "Zhong, Nanshan"

PubPharm (9)

1

The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial)

enthalten in: COPD | 2018

von Zheng, J. | Zhong, N. | Wang, C. | +10

2

Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease : The Chinese Cohort from the LANTERN Study

enthalten in: COPD | 2016

von Zhong, N. | Wang, C. | Zhou, X. | +5

3

Study Design and Interim Outcomes of Guangzhou Institute of Respiratory Disease COPD Biobank

enthalten in: COPD | 2016

von Lu, W. | Zheng, Z. | Chen, X. | +25

4

Study Design and Interim Outcomes of Guangzhou Institute of Respiratory Disease COPD Biobank

enthalten in: COPD | 2016

von Lu, W. | Zheng, Z. | Chen, X. | +25

5

Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study

enthalten in: COPD | 2016

von Zhong, N. | Wang, C. | Zhou, X. | +5

6

Breathlessness or health status in chronic obstructive pulmonary disease : the impact of different definitions

enthalten in: COPD | 2015

von Han, J. | Dai, L. | Zhong, N. | +1

CommentIn: COPD. 2015 Apr;12(2):113-4. - PMID 25938183

7

Breathlessness or Health Status in Chronic Obstructive Pulmonary Disease: The Impact of Different Definitions

enthalten in: COPD | 2015

von Han, J. | Dai, L. | Zhong, N. | +1

8

The association between BMI and COPD : the results of two population-based studies in Guangzhou, China

enthalten in: COPD | 2013

von Zhou, Y. | Wang, D. | Liu, S. | +4

9

The Association between BMI and COPD: The Results of Two Population-based Studies in Guangzhou, China

enthalten in: COPD | 2013

von Zhou, Y. | Wang, D. | Liu, S. | +4

1
[1]